ORPH NASDAQ
Orphazyme A/S
1W: -2.5%
1M: -29.3%
3M: -65.3%
1Y: -89.6%
$0.87
Last traded 2022-03-30 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#?
of ?
Biotechnology
Technical Signal Map
4 Bullish
1 Neutral
8 Bearish
ORPH
—
Orphazyme A/S
N/A
0
GMAB
$142B
Genmab A/S
BULLISH
+82
BAVA.CO
$16B
Bavarian Nordic A/S
BULLISH
+66
FLUO.ST
$550M
FluoGuide A/S
BULLISH
+47
EVAX
$20M
Evaxion Biotech A/S
BULLISH
+42
ALK-B.CO
$44B
ALK-Abelló A/S
BEARISH
-48
INIT.ST
$140M
Initiator Pharma A/S
BEARISH
-75
ASND
$14B
Ascendis Pharma A/S
BEARISH
-78
OZYMF
$30M
Strategic Partners A/S
BEARISH
-78
ZEAL.CO
$17B
Zealand Pharma A/S
BEARISH
-82
GUBRA.CO
$4.9B
Gubra A/S
BEARISH
-82
SANION.ST
$1.3B
Saniona AB (publ)
BEARISH
-82
PEG.CO
$100M
Pharma Equity Group A/S
BEARISH
-91
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| ORPH Orphazyme A/S | — | -7.8 | -129.0 | 662.9 | — | -100.0 | 2 | N/A | -89.6 |
| GMAB Genmab A/S | $142B | 26.5 | 4.0 | 11.9 | 26.2 | -77.7 | 4 | BULLISH | 9.4 |
| BAVA.CO Bavarian Nordic A/S | $16B | 11.0 | 12.2 | 13.3 | 36.0 | -2.4 | 7 | BULLISH | -8.4 |
| FLUO.ST FluoGuide A/S | $550M | -7.7 | -252.1 | -457.6 | — | 109.2 | 5 | BULLISH | -11.4 |
| EVAX Evaxion Biotech A/S | $20M | -0.5 | -109.8 | -260.4 | — | 135.9 | 6 | BULLISH | -27.9 |
| ALK-B.CO ALK-Abelló A/S | $44B | 33.0 | 21.2 | 23.8 | 18.9 | 16.5 | 8 | BEARISH | 8.4 |
| INIT.ST Initiator Pharma A/S | $140M | -3.3 | -333.4 | -2290.2 | — | — | 2 | BEARISH | -40.5 |
| ASND Ascendis Pharma A/S | $14B | 16.7 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BEARISH | 11.6 |
| OZYMF Strategic Partners A/S | $30M | 21.7 | 0.9 | -117.6 | 1019.0 | — | 5 | BEARISH | 0.0 |
| ZEAL.CO Zealand Pharma A/S | $17B | 6.8 | 16.3 | 57.3 | 87.2 | -49.0 | 3 | BEARISH | -33.2 |
| GUBRA.CO Gubra A/S | $4.9B | -26.8 | 207.2 | 468.6 | -87.0 | 793.1 | 8 | BEARISH | -15.8 |
| SANION.ST Saniona AB (publ) | $1.3B | 7.2 | 40.6 | 293.6 | -1280.8 | 25.0 | 6 | BEARISH | -21.8 |
| PEG.CO Pharma Equity Group A/S | $100M | -5.9 | -54.4 | -35.5 | — | — | 3 | BEARISH | -41.9 |
| ORPH Orphazyme A/S | — | -7.8 | -129.0 | 662.9 | — | -100.0 | 2 | N/A | -89.6 |
| GMAB Genmab A/S | $142B | 26.5 | 4.0 | 11.9 | 26.2 | -77.7 | 4 | BULLISH | 9.4 |
| BAVA.CO Bavarian Nordic A/S | $16B | 11.0 | 12.2 | 13.3 | 36.0 | -2.4 | 7 | BULLISH | -8.4 |
| FLUO.ST FluoGuide A/S | $550M | -7.7 | -252.1 | -457.6 | — | 109.2 | 5 | BULLISH | -11.4 |
| EVAX Evaxion Biotech A/S | $20M | -0.5 | -109.8 | -260.4 | — | 135.9 | 6 | BULLISH | -27.9 |
| ALK-B.CO ALK-Abelló A/S | $44B | 33.0 | 21.2 | 23.8 | 18.9 | 16.5 | 8 | BEARISH | 8.4 |
| INIT.ST Initiator Pharma A/S | $140M | -3.3 | -333.4 | -2290.2 | — | — | 2 | BEARISH | -40.5 |
| ASND Ascendis Pharma A/S | $14B | 16.7 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BEARISH | 11.6 |
| OZYMF Strategic Partners A/S | $30M | 21.7 | 0.9 | -117.6 | 1019.0 | — | 5 | BEARISH | 0.0 |
| ZEAL.CO Zealand Pharma A/S | $17B | 6.8 | 16.3 | 57.3 | 87.2 | -49.0 | 3 | BEARISH | -33.2 |
| GUBRA.CO Gubra A/S | $4.9B | -26.8 | 207.2 | 468.6 | -87.0 | 793.1 | 8 | BEARISH | -15.8 |
| SANION.ST Saniona AB (publ) | $1.3B | 7.2 | 40.6 | 293.6 | -1280.8 | 25.0 | 6 | BEARISH | -21.8 |
| PEG.CO Pharma Equity Group A/S | $100M | -5.9 | -54.4 | -35.5 | — | — | 3 | BEARISH | -41.9 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
ORPH vs Benchmarks
ROIC
Revenue Growth
P/E Ratio
ROE
Piotroski F